Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury

Ye Liu, Kazuyuki Hirooka, Akira Nishiyama, Bai Lei, Takehiro Nakamura, Toshifumi Itano, Tomoyoshi Fujita, Jinsong Zhang, Fumio Shiraga

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The purpose of this project was to investigate the effects of the mineralocorticoid receptor antagonist against retinal ischemia-reperfusion injury and identify the aldosterone/mineralocorticoid receptor (MR) system in the rat retina. Retinal ischemia was induced by increasing intraocular pressure to 130 mmHg. Rats were treated with the angiotensin II type 1 receptor (AT1-R) antagonist (candesartan), MR antagonist (spironolactone), or aldosterone. Retinal damage was evaluated at 7 days after the ischemia by measuring the retinal thickness and the number of retinal ganglion cells. Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury. However, there was no protective effect against retinal ischemia-reperfusion injury provided by the combined aldosterone with candesartan treatment. Additionally, pretreatment with aldosterone alone also did not provide any neuroprotective effects against retinal ischemia-reperfusion injury. When rats were treated via local administration of aldosterone in the absence of ischemia, the number of retinal ganglion cells decreased while the retinal thickness remained unchanged. The present findings demonstrated the existence of a local aldosterone/MR system in the retina. Our results also demonstrated that an MR antagonist can attenuate subsequent ischemic damage in the rat retina.

Original languageEnglish
Pages (from-to)116-123
Number of pages8
JournalExperimental Eye Research
Volume96
Issue number1
DOIs
Publication statusPublished - Mar 2012
Externally publishedYes

Fingerprint

Mineralocorticoid Receptors
Mineralocorticoid Receptor Antagonists
Reperfusion Injury
Aldosterone
Spironolactone
Retina
Ischemia
Retinal Ganglion Cells
Angiotensin II Type 1 Receptor Blockers
Neuroprotective Agents
Intraocular Pressure
candesartan
Wounds and Injuries

Keywords

  • Aldosterone
  • Angiotensin II type 1 receptor
  • Mineralocorticoid receptor antagonist
  • Retinal ischemia

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. / Liu, Ye; Hirooka, Kazuyuki; Nishiyama, Akira; Lei, Bai; Nakamura, Takehiro; Itano, Toshifumi; Fujita, Tomoyoshi; Zhang, Jinsong; Shiraga, Fumio.

In: Experimental Eye Research, Vol. 96, No. 1, 03.2012, p. 116-123.

Research output: Contribution to journalArticle

Liu, Ye ; Hirooka, Kazuyuki ; Nishiyama, Akira ; Lei, Bai ; Nakamura, Takehiro ; Itano, Toshifumi ; Fujita, Tomoyoshi ; Zhang, Jinsong ; Shiraga, Fumio. / Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. In: Experimental Eye Research. 2012 ; Vol. 96, No. 1. pp. 116-123.
@article{a3dbf051a4544d2e92adac1e3e44f87f,
title = "Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury",
abstract = "The purpose of this project was to investigate the effects of the mineralocorticoid receptor antagonist against retinal ischemia-reperfusion injury and identify the aldosterone/mineralocorticoid receptor (MR) system in the rat retina. Retinal ischemia was induced by increasing intraocular pressure to 130 mmHg. Rats were treated with the angiotensin II type 1 receptor (AT1-R) antagonist (candesartan), MR antagonist (spironolactone), or aldosterone. Retinal damage was evaluated at 7 days after the ischemia by measuring the retinal thickness and the number of retinal ganglion cells. Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury. However, there was no protective effect against retinal ischemia-reperfusion injury provided by the combined aldosterone with candesartan treatment. Additionally, pretreatment with aldosterone alone also did not provide any neuroprotective effects against retinal ischemia-reperfusion injury. When rats were treated via local administration of aldosterone in the absence of ischemia, the number of retinal ganglion cells decreased while the retinal thickness remained unchanged. The present findings demonstrated the existence of a local aldosterone/MR system in the retina. Our results also demonstrated that an MR antagonist can attenuate subsequent ischemic damage in the rat retina.",
keywords = "Aldosterone, Angiotensin II type 1 receptor, Mineralocorticoid receptor antagonist, Retinal ischemia",
author = "Ye Liu and Kazuyuki Hirooka and Akira Nishiyama and Bai Lei and Takehiro Nakamura and Toshifumi Itano and Tomoyoshi Fujita and Jinsong Zhang and Fumio Shiraga",
year = "2012",
month = "3",
doi = "10.1016/j.exer.2011.12.012",
language = "English",
volume = "96",
pages = "116--123",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury

AU - Liu, Ye

AU - Hirooka, Kazuyuki

AU - Nishiyama, Akira

AU - Lei, Bai

AU - Nakamura, Takehiro

AU - Itano, Toshifumi

AU - Fujita, Tomoyoshi

AU - Zhang, Jinsong

AU - Shiraga, Fumio

PY - 2012/3

Y1 - 2012/3

N2 - The purpose of this project was to investigate the effects of the mineralocorticoid receptor antagonist against retinal ischemia-reperfusion injury and identify the aldosterone/mineralocorticoid receptor (MR) system in the rat retina. Retinal ischemia was induced by increasing intraocular pressure to 130 mmHg. Rats were treated with the angiotensin II type 1 receptor (AT1-R) antagonist (candesartan), MR antagonist (spironolactone), or aldosterone. Retinal damage was evaluated at 7 days after the ischemia by measuring the retinal thickness and the number of retinal ganglion cells. Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury. However, there was no protective effect against retinal ischemia-reperfusion injury provided by the combined aldosterone with candesartan treatment. Additionally, pretreatment with aldosterone alone also did not provide any neuroprotective effects against retinal ischemia-reperfusion injury. When rats were treated via local administration of aldosterone in the absence of ischemia, the number of retinal ganglion cells decreased while the retinal thickness remained unchanged. The present findings demonstrated the existence of a local aldosterone/MR system in the retina. Our results also demonstrated that an MR antagonist can attenuate subsequent ischemic damage in the rat retina.

AB - The purpose of this project was to investigate the effects of the mineralocorticoid receptor antagonist against retinal ischemia-reperfusion injury and identify the aldosterone/mineralocorticoid receptor (MR) system in the rat retina. Retinal ischemia was induced by increasing intraocular pressure to 130 mmHg. Rats were treated with the angiotensin II type 1 receptor (AT1-R) antagonist (candesartan), MR antagonist (spironolactone), or aldosterone. Retinal damage was evaluated at 7 days after the ischemia by measuring the retinal thickness and the number of retinal ganglion cells. Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury. However, there was no protective effect against retinal ischemia-reperfusion injury provided by the combined aldosterone with candesartan treatment. Additionally, pretreatment with aldosterone alone also did not provide any neuroprotective effects against retinal ischemia-reperfusion injury. When rats were treated via local administration of aldosterone in the absence of ischemia, the number of retinal ganglion cells decreased while the retinal thickness remained unchanged. The present findings demonstrated the existence of a local aldosterone/MR system in the retina. Our results also demonstrated that an MR antagonist can attenuate subsequent ischemic damage in the rat retina.

KW - Aldosterone

KW - Angiotensin II type 1 receptor

KW - Mineralocorticoid receptor antagonist

KW - Retinal ischemia

UR - http://www.scopus.com/inward/record.url?scp=84857801152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857801152&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2011.12.012

DO - 10.1016/j.exer.2011.12.012

M3 - Article

C2 - 22200488

AN - SCOPUS:84857801152

VL - 96

SP - 116

EP - 123

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 1

ER -